Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check4 days agoChange DetectedThe page has been updated with new contact numbers and a new revision version, while previous contact numbers and an older revision have been removed.SummaryDifference0.8%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check19 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.7%
- Check26 days agoChange DetectedThe page has been updated to reflect new registry identifiers and site information, including the addition of specific oncology institutions and a revision update to version 2.16.0.SummaryDifference2%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check62 days agoChange DetectedThe webpage has been updated to include new information about the study on Small Cell Lung Carcinoma, specifically detailing the investigational agents and their identifiers, as well as the collaborators involved. Notably, the previous detailed description of the study's methodology and inclusion/exclusion criteria has been removed.SummaryDifference36%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.